Genmab cancer drug incomes surpass USD 400m in Q3
The Danish biotech firm is maintaining its full-year guidance, which was recently raised due to strong Darzalex sales.
by marketwire, translated by catherine brett
Favorable currency conditions and strong sales of cancer drug Darzalex led Genmab to upgrade its financial guidance just under a week ago, and now, the firm’s Q3 report reveals significant growth.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab upgrades guidance
For subscribers
Analyst spots strong figures behind Genmab upgrade
For subscribers
Genmab secures global rights to Scancell antibody
For subscribers
